Pharmacyclics LLC - Company Profile
Powered by
All the data and insights you need on Pharmacyclics LLC in one report.
- Save hours of research time and resources with
our up-to-date Pharmacyclics LLC Strategy Report
- Understand Pharmacyclics LLC position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Pharmacyclics LLC (Pharmacyclics) is a biopharmaceutical company that discovers, develops and commercializes novel small-molecule drugs for the treatment of cancer and immunological disorders. Pharmacyclics has one marketed product, Imbruvica (ibrutinib) is an once-daily, first-in-class Bruton’s tyrosine kinase (BTK) inhibitor targeting anti-inflammatory and autoimmune indications. It is approved for use in various indications in the US and is the only product to have received four breakthrough therapy designations by the USFDA.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer